Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Had a call with Turner Pope last week. They wanted to know the reason for investing, my current feeling towards the share and management team. TP are contacting people who registered for tomorrow’s presentation. I have agreed to a follow up call once our CEO has spoken. I did ask about the 40 days silence since the placing. It is needed because of USA rules.
As the majority of shares are owned by PIs this “how are your feeling” approach will give the company some visibility on how shareholders would act. We might be asked to vote for ???
Anybody else notice Page three of this week's Sunday Times travel section, article Q & A The Ultimate Travel Guide, heading Where Can I Get A Test Overseas?
Last two sentences:
"All the big tour operators will make sure that provisions are in place to test their customers before return to the UK. Government discussions about whether to allow people in the green list destinations to take a free NHS lateral-flow test are in progress."
Better be a great LFT.
Published 16 November 2020
From:
Department of Health and Social Care
Lab worker holding a swab test
Two new very high throughput laboratories will open in early 2021, cementing the UK as a world leader in diagnostics and creating up to 4,000 jobs
Both labs, the first based in Leamington Spa and the second in Scotland, will add 600,000 of daily testing capacity altogether when operating at full capacity, meaning faster turnaround times for test results
These new labs form a key part of the UK’s national infrastructure to respond to future epidemics as well as adding diagnostic capacity for other critical illnesses, including cancer
Today the government is announcing the opening of 2 new ‘megalabs’ which will become operational in early 2021. The 2 labs, based in Leamington Spa with a second lab located in Scotland, will each add 300,000 to the UK’s daily testing capacity when operating at full capacity.
Cutting-edge technology made by British manufacturers will be used in both labs, including automation, robotics and consumables. This means more tests will be processed more quickly and at a lower cost, and therefore faster turnaround times for test results.
As part of its response to COVID-19, the government has already established the largest network of diagnostic testing facilities in British history. The announcement today of these next generation of diagnostic facilities represents an investment in the UK’s epidemic response infrastructure for the future. Not only will the 2 labs be used to process COVID-19 tests, but the significant boost in diagnostic capabilities will be used for critical illness including cancer, cardiovascular and metabolic diseases.
The new labs will generate local employment, with each very high throughput laboratory having a multi-skilled workforce of up to 2,000 people once fully staffed, and operating at full capacity 24/7, including the associated manufacturing and supply chain. A recruitment drive has already started for the Leamington Spa lab, and a campaign is due to start shortly in Scotland once site details are confirmed.
Health Secretary Matt Han**** said:
The radical expansion of testing has been one of the successes of this pandemic, as it means more people can get a test more conveniently than ever before. We didn’t go into this crisis with a significant diagnostics industry, but we have built one, and these 2 mega labs are another step forward. Transforming the UK’s diagnostic facilities is not only essential to beating this virus, but it is necessary to build back better - so we are better prepared in future for testing on a massive scale.
These mega labs are future-proofing our national infrastructure to respond to future epidemics and improving care for other diseases, such as cancer. The new labs build on our existing testing network which we created in a matter of months and confirms the UK as a world leader in diagnostics.
I am taking part in a Covid-19 testing study. Just received the test kit. Nasal swab that has to be sent off to the lab. The 11 page instruction manual is worse than instructions to build IKEA furniture. I have to build a cardboard box for the test then book a courier. Result in 72 hours.
LFT has to be the way forward. Looking forward to Monday's presentation.
Found this advice on PHE website:
11th May 2020
Some manufacturers are selling products containing COVID-19 testing kits that allow a swab or other type of sample to be taken at home or in the pharmacy setting, followed by a very rapid result within about 10 minutes.
These tests are different from the postal kits that are being used whereby the swab is taken by you at home and then returned by post or courier. (Refer to essential worker testing for more information.)
The current view by PHE is that use of products that give a very rapid result is not advised:
Some of these products look for virus while others look for the body’s immune response to the virus. Such tests are very rapid and can work on a range of specimens including serum, plasma or finger-prick whole blood
There is little information on the accuracy of these rapid point of care tests, or on how a patient’s antibody response develops or changes during COVID-19 infection. It is not known whether either a positive or negative result is reliable
currently there is no published evidence about the suitability of these rapid point of care tests for diagnosing COVID-19 infection in a community setting.
Also on the 11th May AVACTA CEO stated:
is a major accomplishment to have generated Affimer reagents that can work in pairs as well as singly, as this opens up the potential for detecting the detached spike proteins as well as the intact virus particles, which means that we should have the best possible COVID-19 antigen test.
Key points are PHE at the moment do not recommend any point of care tests and we have the best possible test. Exciting.
My first job was working in a TV and video shop. VHS won the fight on cost. The fact that Avacta is the "Betamax of have you got the virus" meaning the best quality test as well as having a cost advantage bodes well for medium to long term investors.
As a new investor to this sector many thanks to Miles McNulty and RichKen for their helpful words. Caught Avacta's CEO on Sky News. 10 minutes later I had bought £10k worth of stock.
I would like to understand where are the limitations for production? Can Avacta produce product that can service billions of tests? Can distributors produce enough tests to service demand? Any hard facts would be greatly appreciated.
PTSG is a buy and build model, consolidating regional businesses into a nationwide solution.
If you are a multi-site organisation, you can contract with one of the UK PLC FM organisations for compliance services (expensive and risky Carillion/Interserve) or deal with lots of regional businesses to fulfil not sending the board of directors to jail. PTSG has become a one stop national shop for compliance which is a more cost effective route and simpler solution that the two alternatives.
This type of budget is driven by legislation and would be a the top of the spend list for most mature organisations.
£200m Government funding for cladding replacement will benefit PTSG. The larger multisite organisations will want to use PTSG. One company, one big invoice, one solution.
Debtor days is an issue but getting better. There is a simple solution. PTSG does not issue the compliance certificate until payment is made.
I am part owner of a UK national FM business. Having met the directors of PTSG and understand the strategy I am very comfortable with the plan. UK PLC FM share prices have been battered. This is a high margin business with 88% renewal rates and long term contracts and growing.
At some point PTSG will be purchased by one of the big FM companies. John Foley has a successful history building a nationwide FM business and selling the company to a large player:
hxxps://www.birminghampost.co.uk/business/maclellan-group-goes-to-interserve-3983203
Major top up today.
Results out tomorrow.
EPS December 2016 2.16p Share price when announced in March circa �1.00. Projected 2017 EPS 10.8p (Glaws2 post). Current share price �1.90. Could this price double when the results are published in March which would be inline with the EPS/Share price?
PTSG won two categories at this week's PFM awards. Came top for partners in expert services single site and partners in retail with Marks and Spencer. The good news keeps on coming.
I was lucky enough to buy Restore at 34p and exited a happy bunny at �3.76, to purchase PTSG. Restore is a buy and build model focusing on high margin Facilities Management contracts. Restore's current price is �5.24. Once the acquired management has been paid off earnings per share and stock price rises as the position washed through. PTSG are following the same path as Restore. Many acquisitions then exceptionals which will wash through to be reflected in the earning per share and stock price. I would argue that PTSG's multiples and cash acquired for acquisitions have been outstanding. These were the two key comments for me from the Chief Executives Report "Turnover and operating profit have gained considerable momentum over the first half of the year, instilling confidence that we will be in a position of real strength by the year-end. So far 2017 has been quite unlike any other year in our ten-year history. It would be remiss of me not to reference the fact that the first half of the year was characterised by high-profile events which have had a significant effect on all who operate within facilities management". The next set of results will in part show how exciting this model, company and management is now and into the future. I also expect the management to sell the company as they did with MacLennan in 2006. Safety compliance changes to the FM industry will only strengthen PTSG. Strong long term buy. DYOR
Mon, 7th August 2017 - 14:33 iii post Share this I have long talked up the white-hot investment potential of Boohoo (LSE:BOO), its galloping popularity with clothes shoppers across the globe likely to lay the bedrock for robust earnings growth in the years ahead. But those seeking brilliant bottom-line expansion also need to check out Premier Technical Services (LSE:PTSG) today, in my opinion. The niche services provider stormed to fresh record peaks late last week, although first-half results released today have prompted some bouts of profit-booking. Premier Technical Services was last dealing 4% lower from Friday's close. The Castleford company noted that it had "previously announced that it was performing well in the first half," and that "this performance has continued." It commented that it "has noticed an increase in compliance awareness among our 17,000 customers and we have experienced continuing sales growth and strong levels of orders in the year to date." Premier Technical Services has ground out new contract wins across all its disciplines, it advised, including a number of multi-discipline framework agreements with new and existing customers. Contract renewal rates remain high, the company added, which are underpinning its organic growth plans. In other news, it noted that its acquisition of lightning protection and steeplejack play BEST last month "has started well and is progressing to plan," while the purchase of Nimbus Lightning Protection at the start of the year is performing in line with expectations. And the specialist services giant announced that trading during the the first few weeks of the second half has transpired as expected. Hot numbers There is much to be excited about over at Premier Technical Services, in my opinion, with recent acquisitions providing plenty of new sales opportunities and organic revenues also rattling higher. The firm saw underlying organic sales detonate 20% in 2016. City analysts agree that the West Yorkshire business is in terrific shape, with the number crunchers currently predicting healthy earnings growth of 77% and 6% in 2017 and 2018 respectively. While it deals on a pretty vanilla forward P/E ratio of 16.6 times, a sub-1 PEG rating of 0.2 suggests the stock is actually brilliantly priced relative to its growth prospects. I reckon the services star is worthy of serious consideration at current prices.
Qd22. Agree something smells. Purchased circa £800 through HL at 9.30 this morning. No record of the trade. Very happy holder. Worked within FM at board level for 12 years. Met some of the Directors of PTSG. This is and will continue to be a star performer. Great leadership, product and plan.
£2m of shares traded today. As a long term holder very happy with the recent results and share price. I have met the very impressive management team who built MacLellan from a small FM company and sold the business to Interserve for a 9 figure sum. Directors and CEO mid 50s. This feels like the last and most impressive piece of work from proven and experienced FM talent.
According to PTSG's website they have won 9 contracts since 30th June including work in Iraq and Barbados. hxxp://www.ptsg.co.uk/news/ Looking forward to a record set of results.